Marshall Wace, LLP Vir Biotechnology, Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $230,144 - $270,716	-9,920 Reduced 11.87%	73,641 $1.81 Million
Q1 2023 May 15, 2023	SELL	$22.26 - $30.85 $2.55 Million - $3.53 Million	-114,429 Reduced 57.8%	83,561 $1.94 Million
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $2.96 Million - $4.18 Million	-148,286 Reduced 42.82%	197,990 $5.01 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $1.65 Million - $2.81 Million	90,200 Added 35.22%	346,276 $6.68 Million
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $4.89 Million - $6.84 Million	256,076 New	256,076 $6.52 Million
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $7.46 Million - $14.1 Million	-352,171 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $9.09 Million - $15.9 Million	293,552 Added 500.78%	352,171 $14.7 Million
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $2.05 Million - $3.2 Million	58,619 New	58,619 $2.55 Million
Q2 2021 Aug 13, 2021	SELL	$38.75 - $51.0 $1.53 Million - $2.02 Million	-39,560 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$26.34 - $83.07 $1.04 Million - $3.29 Million	39,560 New	39,560 $2.03 Million

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.